206 related articles for article (PubMed ID: 9446659)
41. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
42. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
43. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
44. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Mundhada S; Luthra R; Cano P
BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
[TBL] [Abstract][Full Text] [Related]
45. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
[TBL] [Abstract][Full Text] [Related]
46. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
Matte CC; Cormier J; Anderson BE; Athanasiadis I; Liu J; Emerson SG; Pear W; Shlomchik WD
Blood; 2004 Jun; 103(11):4353-61. PubMed ID: 14982874
[TBL] [Abstract][Full Text] [Related]
47. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
[TBL] [Abstract][Full Text] [Related]
48. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
49. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
[TBL] [Abstract][Full Text] [Related]
50. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
[TBL] [Abstract][Full Text] [Related]
51. BCR-ABL-specific CD4
Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
[TBL] [Abstract][Full Text] [Related]
52. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
Scheich F; Duyster J; Peschel C; Bernhard H
Blood; 2007 Oct; 110(7):2556-60. PubMed ID: 17579186
[TBL] [Abstract][Full Text] [Related]
53. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function.
Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692
[TBL] [Abstract][Full Text] [Related]
54. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.
Krause DS; Van Etten RA
Blood; 2004 Dec; 104(13):4236-44. PubMed ID: 15308567
[TBL] [Abstract][Full Text] [Related]
55. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
[TBL] [Abstract][Full Text] [Related]
56. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
57. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
58. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
59. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
60. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Orsini E; Calabrese E; Maggio R; Pasquale A; Nanni M; Trasarti S; Tafuri A; Guarini A; Foa R
Leuk Res; 2006 Jul; 30(7):785-94. PubMed ID: 16527350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
